Long-term follow-up in superficial transitional cell carcinoma of the bladder: prognostic factors for time to first recurrence, recurrence rate, and survival. Final results of a randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone. EORTC Genitourinary Tract Cancer Cooperative Group

Prog Clin Biol Res. 1989:303:481-90.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Carcinoma, Transitional Cell / drug therapy
  • Carcinoma, Transitional Cell / surgery*
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Doxorubicin / therapeutic use*
  • Ethers / therapeutic use*
  • Ethoglucid / therapeutic use*
  • Europe
  • Follow-Up Studies
  • Humans
  • Multicenter Studies as Topic
  • Prognosis
  • Random Allocation
  • Urinary Bladder / surgery*
  • Urinary Bladder Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / surgery*

Substances

  • Ethers
  • Ethoglucid
  • Doxorubicin